Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments

Article Pathology

Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer

Gianluca Gragnano et al.

Summary: In this study, liquid biopsy using Idylla KRAS assay showed promising results in assessing KRAS p.G12C mutation in non-small cell lung cancer patients. The study demonstrated that Idylla NSCLC KRAS liquid biopsy assay may be a reliable tool for detecting KRAS p.G12C mutation.

JOURNAL OF CLINICAL PATHOLOGY (2022)

添加到收藏夹

Article Oncology

Liquid biopsy enters the clinic - implementation issues and future challenges

Michail Ignatiadis et al.

Summary: The approval of liquid biopsy assays for detecting genetic alterations in plasma cell-free DNA has marked a tipping point for the clinical use of this technology, especially in patients with advanced-stage cancer. The next frontier is likely to be the systemic treatment of patients with 'ctDNA relapse' and other potential future applications include cancer screening and diagnosis.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

Sotorasib effective in KRAS-mutant NSCLC

Peter Sidaway

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Cell Biology

Evolutionary Mechanisms of Cancer Suggest Rational Therapeutic Approaches

Alessio Balzerano et al.

Summary: The goal of personalized cancer medicine is to identify specific mutations with prognostic and therapeutic value for tailor-made therapy. However, the main obstacle lies in intratumor heterogeneity and clonal evolution, which can lead to drug resistance. New technologies like next-generation sequencing play a crucial role in profiling cancer (epi)genomic landscapes.

CYTOGENETIC AND GENOME RESEARCH (2021)

添加到收藏夹

Article Chemistry, Medicinal